Akili raises an additional $11.9M; brings Amgen, Merck, Pfizer and Shire to the digital medicine table

By SharpBrains | July 21, 2016

—– Akili Adds Amgen Ven­tures and M Ven­tures* to Series B Financ­ing, Increas­ing Round to $42.4 Mil­lion (press release): “Akili Inter­ac­tive Labs, Inc. (“Akili”), a dig­i­tal med­i­cine com­pa­ny devel­op­ing nov­el, non-phar­­ma­­co­log­i­­cal ther­a­peu­tics and diag­nos­tics for cog­ni­tive dis­or­ders, today announced an $11.9 mil­lion expan­sion of its recent Series B financing. 

Read More